A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. - Wikidata - wikimedia - TriplyDB

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

http://www.wikidata.org/entity/Q53735140

about

Recent advancements of bortezomib in acute lymphocytic leukemia treatment The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice Novel agents for the treatment of childhood acute leukemia.GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.Improving access to novel agents for childhood leukemia.Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade.Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim Molecular profiling of childhood cancer: Biomarkers and novel therapies A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)Advances in paediatric cancer treatment Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.Neurotoxicity of biologically targeted agents in pediatric cancer trials A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia Targeted drug discovery for pediatric leukemia.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Novel targeted drug therapies for the treatment of childhood acute leukemia Molecular therapeutic approaches for pediatric acute myeloid leukemia.Proteasome inhibitors in acute leukemia.Novel therapies for children with acute myeloid leukaemia.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Novel targeted therapies in acute lymphoblastic leukemia.Novel approaches to pediatric leukemia treatment.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.

P2860

Q26829613-0DF44A82-97E8-41D0-A213-1654C515DBFB Q28477838-49CCE7EA-DDD4-4CCB-8DDD-CCCF206389E3 Q28485441-200E5884-E5D0-40E9-BCD0-DB699B98EF27 Q28487205-779ACE15-6FF1-4F59-A3D9-F8D8F5146B0F Q28534151-DB1438D0-387B-49A3-AB47-360116FD106D Q30248842-F9F15C3C-611D-4956-8B6A-5A1433864743 Q30252776-9770531B-19AD-4378-83F5-FBA66836219F Q33303627-A7090D69-EEC5-4222-8C28-A32698C65868 Q33388541-CE014D9E-9F2C-4630-8D6C-E4216B535318 Q33711119-41A45C1F-39ED-4151-9A96-A9258AAE4E6A Q33745227-CD233F47-5BE3-4760-9ADD-49A3EFE50755 Q33828073-3051BE1A-F5DE-4DA3-81EA-93B3A37407DA Q34051168-35E4B342-F92D-43D3-8B58-A968FD64440F Q34585047-AD9EEF9C-ACB7-4FD9-B014-7A681030C49B Q35175035-ACA20612-9ED9-4B51-AE2C-5575F5B5A614 Q35192790-0170033E-773D-4864-B6F1-D216AEEB9ED1 Q35208033-51B6007D-F4EA-4DCF-8292-D63EFABD2EF0 Q35688742-6B275733-516F-4AD9-AA1E-B3FCB1926487 Q35889130-A1C1A9B6-97BF-4C59-909B-8B0006F475C2 Q35957567-F6E256DE-0989-4777-B2AF-EA93808E82F4 Q35982670-C4A6BF1D-B173-4F30-AB82-5B451DC3E0BC Q36250783-18F4AECA-394C-4740-A6B2-E2C3575908D9 Q36438027-FD99663A-25B3-47FA-AA28-AE97F3931C73 Q36508630-9E3819CB-BFCB-4DC7-A839-9B67C4D0DABE Q36646486-838F5216-79E9-4F47-A3E1-F6DB101A0F48 Q36738818-2D43CCD6-89B2-487C-863A-D150AEB145CD Q36766221-586614CD-6768-4DFD-AD2F-AEF578277866 Q36955757-2BDDB7F9-910E-48EA-9525-943E5A9BCED7 Q36989223-8A7BF152-59E0-4F62-80A5-D713EC1B100E Q37233146-827B9C45-BC1F-47B7-9C22-66F8038DC4E2 Q37301320-1FAD278D-E314-41F5-B107-A77750048F31 Q37377911-60AC0501-5901-455F-BD6A-5144A9CDFCE3 Q37477482-AFB23976-1E04-4733-9BDD-AA67251DDC14 Q37643136-3CE6AB5A-60F1-4F41-BDBC-64BF68F7E395 Q38088003-A5D1A807-3A0C-44AB-BAE4-01E5B503D131 Q38096798-50FD8185-7302-4672-8C91-9197A86C438A Q38097334-F6E91701-785F-4C8C-80E0-AE6BAC0540B9 Q38120551-AA819F59-C360-4A36-91BD-49EBC19B02D2 Q38500371-6327058D-7C92-4AFE-BC01-D0FC839A580A Q38813978-877EE881-C8BD-42AB-8CC9-9CCA8F64DA65

P2860

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

http://www.wikidata.org/entity/Q53735140

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@en

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@nl

type

label

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@en

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@nl

prefLabel

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@en

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@nl

P1433

Q53735140-7E783A34-B346-47A9-BF49-788B3D8A36BC

P1476

Q53735140-A048E8AE-BC77-409B-8308-F01C0DC06F39

P2093

Q53735140-2ED8A990-E81B-4CA5-B9A7-4E96AEB8117E

Q53735140-43120F25-D96A-4BF0-B76E-87D440015354

Q53735140-70030F76-27AD-4BE0-A714-B5C02F0EC363

Q53735140-75C92ED9-2C32-43C0-950E-542710B2ED76

Q53735140-90ED033B-EDBB-439B-9C08-3D8668B08A16

Q53735140-93E26F7A-1F12-4E4F-A306-30CC728A3845

Q53735140-9BC35B00-9EA0-4677-AFD2-BC300CCCB6FE

Q53735140-B23C4CAB-E69D-419A-AFA4-FFA748850352

Q53735140-DA44293C-F54C-4228-9864-C363C0C699F8

Q53735140-EFA3AD9B-62A4-476B-B399-0FB3673EA23D

P304

Q53735140-23B20B1A-BCF3-4D35-842A-236BE89B59E8

P31

Q53735140-501C55A1-7F10-4209-B8F5-1E0A1780CB11

P356

Q53735140-9378B7D4-860F-4C06-AD7E-DF15CBD2DDBE

P407

Q53735140-31E9B1AA-5FFF-4F42-8432-06D77582D7FA

P433

Q53735140-BD51BC3E-7DFF-40E7-9844-564817772C48

P478

Q53735140-D016130B-3436-48D1-9584-3CE6D1344C87

P50

Q53735140-601F1E9F-326F-413E-BAAE-937C1429F25B

P577

Q53735140-809BFA85-72EA-4B58-B09D-25DB36CD2808

P698

Q53735140-200C927B-729E-49F3-BA9A-A4F596A49391

P921

Q53735140-ABEE53DE-3A2E-4D2D-8464-3820E9846865

Q53735140-DDB26BC4-A2AC-4449-8098-CD0889F67FDC

P356

1078-0432.CCR-06-2173

P1433

Clinical Cancer Research

P1476

A phase 1 study of the proteas ...... ildren's Oncology Group study.

@en

P2093

Adam H Brockman

http://www.w3.org/2001/XMLSchema#string

Ashish M Ingle

http://www.w3.org/2001/XMLSchema#string

Debananda Pati

http://www.w3.org/2001/XMLSchema#string

John Wright

http://www.w3.org/2001/XMLSchema#string

Lisa R Bomgaars

http://www.w3.org/2001/XMLSchema#string

Martin Paton

http://www.w3.org/2001/XMLSchema#string

Patrick A Thompson

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Sharon E Plon

http://www.w3.org/2001/XMLSchema#string

Terzah M Horton

http://www.w3.org/2001/XMLSchema#string

P304

1516-1522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-2173

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17332297

http://www.w3.org/2001/XMLSchema#string

P921